(M2 PressWIRE Via Acquire Media NewsEdge) BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Tuesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Tuesday there were 3967 companies with "abnormal" market making, 1361 companies with positive Friction Factors and 3850 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage gain per share Tuesday and low price friction (bullish). This means that there was more buying than selling in the stocks and their stock prices rose faster with less Friction. Progenics Pharmaceuticals Inc (NASDAQ:PGNX), SOLOMON GOLD CORP (NASDAQ:SGOC), Vanda Pharmaceuticals Inc (NASDAQ:VNDA), Catalyst Pharmaceutical Partners Inc (NASDAQ:CPRX), Affymax Inc (OTC:AFFY), CardioNet Inc (NASDAQ:BEAT). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
Market Maker Friction Factor is shown in the chart below:
Symbol Change Percent Buy Volume Buy %% Sell Volume Sell %% Net Volume Friction
PGNX $0.870 23.53% 1,113,025 54.78% 913,310 44.95% 199,715 2,296
SGOC $0.970 70.80% 2,952,867 52.70% 2,564,811 45.77% 388,056 4,001
VNDA $2.550 25.37% 2,477,246 49.36% 2,423,982 48.29% 53,264 209
CPRX $0.170 18.51% 3,464,355 60.88% 2,225,699 39.12% 1,238,656 72,862
AFFY $0.170 19.99% 1,929,204 50.38% 1,751,705 45.75% 177,499 10,447
BEAT $1.780 55.45% 3,499,277 50.65% 3,401,011 49.23% 98,266 552
Analysis of the Friction Factor chart above shows that each of the six stocks mentioned above have high net buy volumes (buy volume, sell volume) and low price friction in their stocks. The Friction Factor displays how many more shares of buying than selling are required to move a stock higher by one cent or how many more shares of selling than buying moves a stock lower by 1 cent.
For example, the chart above shows PGNX with a dollar gain Tuesday of $0.87000 and a Friction Factor of 2,296 shares. That means that it only took 2,296 more shares of buying than selling to move PGNX higher by one penny. The Market Makers are currently allowing the stock to rise quickly (low friction). The combination of low friction and positive market direction can drive prices higher much faster than normal.
Progenics Pharmaceuticals Inc (NASDAQ:PGNX) - Progenics Pharmaceuticals, Inc. engages in research and development of biotechnology product candidates in the areas of oncology, virology, supportive care, and gastroenterology worldwide. The company offers RELISTOR (methylnaltrexone bromide), a subcutaneous injection for the treatment of opioid induced constipation (OIC) in patients with advanced illnesses, such as cancer. It is also developing RELISTOR, a subcutaneous injection for the treatment of OIC in patients with non-cancer pain; and RELISTOR-Oral, which has completed Phase III testing for the treatment of OIC in patients with non-cancer pain. The company s principal product candidate under development is PSMA ADC, which is in Phase I trial in men with advanced prostate cancer. PSMA ADC is an antibody-drug conjugate (ADC) that targets prostate specific membrane antigen (PSMA), a protein found on the surface of prostate cancer tumor cells, as well as on the neovasculature of various other types of solid tumors. In addition, the company is developing PI3K, a pre-clinical stage novel multiplex phosphoinositide 3-kinase inhibitor for blocking signaling pathways that are critical in the growth of aggressive cancers. It has license agreement with Salix Pharmaceuticals, Inc. for the development and commercialization of RELISTOR worldwide other than Japan. Progenics Pharmaceuticals, Inc. was founded in 1986 and is based in Tarrytown, New York..
SOLOMON GOLD CORP (NASDAQ:SGOC) - SGOCO Group, Ltd. engages in designing and developing LCD/LED monitors, TVs, and application specific products for sale primarily to the flat panel display market in China. It offers LCD/LED monitors; LCD/LED televisions; application specific LCD/LED display products, such as tablet PCs for commercial and consumer use, e-reader notebooks, cell phone devices, mobile Internet devices, e-boards that integrate software and hardware functionalities, rotating screens, CCTV monitors for security systems, billboard monitors for advertising, public notice systems, and touch screens for non-keyed entries; and application specific multimedia systems and services, including display products and televisions with software control systems for commercial customers. The company also develops LCD/LED systems solutions for industry clients, such as educational institutions, government departments, and corporate offices. It sells its products under SGOCO, No. 10, POVIZON, TCL, and Founder brand names through electronics distributors and trading companies, as well as to distributors under the SGOCO Image program. The company was formerly known as SGOCO Technology, Ltd. and changed its name to SGOCO Group, Ltd. in November 2010. SGOCO Group, Ltd. was founded in 2005 and is based in Beijing, China..
Vanda Pharmaceuticals Inc (NASDAQ:VNDA) - Vanda Pharmaceuticals Inc., a biopharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system disorders. It offers Fanapt, an oral formulation of a compound for the acute treatment of schizophrenia in adults. The company is also developing Fanapt, a Phase II clinical trial injectable formulation for the treatment of Schizophrenia. Its products in clinical development also include Tasimelteon, which completed Phase III clinical trials for the treatment of sleep and mood disorders, including circadian rhythm sleep disorders; and Tasimelteon that is in Phase IIb/III trials for the treatment of major depressive disorder. Vanda Pharmaceuticals Inc. also indents to conduct clinical trials to support the use of Tasimelteon as a circadian regulator. The company was incorporated in 2002 and is headquartered in Washington, District of Columbia..
Catalyst Pharmaceutical Partners Inc (NASDAQ:CPRX) - Catalyst Pharmaceutical Partners, Inc., a development-stage specialty pharmaceutical company, focuses on the development and commercialization of prescription drugs targeting diseases and disorders of the central nervous system with a focus on the treatment of addiction and epilepsy. It is evaluating, its lead product candidate, CPP-109, a GABA aminotransferase inhibitor candidate, which is under Phase II(b) clinical trial for the treatment of cocaine and methamphetamine addiction, as well as focuses on evaluating CPP-109 for the treatment of other addictions and other selected central nervous system indications. The company is also developing CPP-115, a GABA aminotransferase inhibitor in Phase I(a) trial for various indications, including drug addiction, epilepsy, and for other selected central nervous disease indications. It has license agreements with Brookhaven Science Associates, LLC on various patents and patent applications relating to the use of vigabatrin as a treatment for cocaine and other addictions, and obsessive-compulsive disorders. The company was founded in 2002 and is headquartered in Coral Gables, Florida..
Affymax Inc (OTC:AFFY) - Affymax, Inc., a biopharmaceutical company, engages in the development of drugs for the treatment of serious and life-threatening conditions in the United States. It offers OMONTYS (peginesatide) Injection for the treatment of anemia in chronic kidney disease in adult patients on dialysis. OMONTYS is a synthetic, peptide-based erythropoiesis stimulating agent designed to stimulate production of red blood cells. The company has strategic alliance agreement with Takeda Pharmaceutical Company Limited to develop and commercialize OMONTYS. Affymax, Inc. was founded in 2001 and is headquartered in Palo Alto, California..
CardioNet Inc (NASDAQ:BEAT) - CardioNet, Inc. provides real-time ambulatory outpatient management solutions for monitoring clinical information regarding an individual's health in the United States. The company focuses on the diagnosis and monitoring of cardiac arrhythmias through its Mobile Cardiac Outpatient Telemetry (MCOT) system, and event and Holter monitor. Its MCOT system is a ambulatory and real-time arrhythmia monitoring solution that incorporates a patient-worn sensor attached to leads, which captures ECG data and communicates wirelessly with a compact monitor that analyzes incoming information by applying proprietary algorithms designed to detect arrhythmias and eliminate data noise; and automatically transmits the ECG data to the CardioNet Monitoring Center, where cardiac monitoring specialists analyze the sent data, respond to urgent events, and report results in the manner prescribed by the physician. The company also provides event, and Holter and pacemaker monitoring services for cardiologists and electrophysiologists who prefer to use a single source of arrhythmia monitoring services. In addition, it engages in developing, manufacturing, and marketing medical devices and related software to medical companies, clinics, and hospitals. The company was incorporated in 1994 and is headquartered in Conshohocken, Pennsylvania..
BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:
REGULATORY & COMPLIANCE NEWS
Friction Factor -- market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements"
RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO
INVESTMENTS & TRADING
SqueezeTrigger -- 29 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.
Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.
Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.
Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.
Pattern Scan -- automates tracking of every technical pattern and predicts time and size of move in all stocks.
GATS (Global Automated Trading System) -- tracks all known trading strategies and qualifies and quantifies which are working best in real time.
BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. BUYINS.NET has not been compensated by any of the above mentioned companies. Past performance is not indicative of future results. Please visit our web site, www.buyins.net , for complete risks and disclosures.
((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.com on the world wide web. Inquiries to firstname.lastname@example.org)).